July 22, 2015

Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015

Results Demonstrate Statistically Significant Reduction of Beta Amyloid, Dose-Dependent Slowing of Clinical Decline and Acceptable Safety.

Read full article